16.46
-1.44(-8.04%)
Currency In USD
| Previous Close | 17.9 |
| Open | 17.01 |
| Day High | 17.22 |
| Day Low | 16 |
| 52-Week High | 19.98 |
| 52-Week Low | 9.03 |
| Volume | 1.48M |
| Average Volume | 674,601 |
| Market Cap | 1.24B |
| PE | -19.36 |
| EPS | -0.85 |
| Moving Average 50 Days | 16.96 |
| Moving Average 200 Days | 13.88 |
| Change | -1.44 |
If you invested $1000 in Zymeworks Inc. (ZYME) since IPO date, it would be worth $1,266.15 as of November 10, 2025 at a share price of $16.46. Whereas If you bought $1000 worth of Zymeworks Inc. (ZYME) shares 5 years ago, it would be worth $403.13 as of November 10, 2025 at a share price of $16.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
GlobeNewswire Inc.
Oct 23, 2025 4:30 PM GMT
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall response rate in gynecological can
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
GlobeNewswire Inc.
Oct 16, 2025 10:00 AM GMT
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for diffic
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
GlobeNewswire Inc.
Oct 13, 2025 8:00 PM GMT
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer.Data from the Phase 1 t